Company: IMRX
Filing Date: 2025-06-23
Form Type: 424B5
Source: 0001104659-25-061344
Chunk: 1

Company: Immuneering Corp
Filing Date: 2025-06-23
Form: 424B5
Chunk 1
---
 subject to the sales limitations of General Instruction I.B.6 of Form S-3 with respect to the registration statement of which the ATM Prospectus, as amended hereby, forms a part. If we become subject to the limitations of such General Instruction I.B.6 in the future, we will file another supplement to the ATM Prospectus.

Since our entry into the Agreement, we have offered and sold 6,155,556shares of Class A common stock for gross proceeds of $18,706,156.11 pursuant to the Agreement. Accordingly, because we are no longer subject to the sales
limitations of such General Instruction I.B.6, we may offer and sell up to an additional $31,293,843.89 of shares of Class A common stock
pursuant to the Agreement.

Our Class A common stock is listed on The Nasdaq Global Market under the symbol “IMRX”. On June 20, 2025, the last reported sale price of our Class A common stock on The Nasdaq Global Market was $2.56 per share.

Investing in our Class A common stock involves a high degree of risk. Before making an investment decision, please read the information under the heading “Risk Factors” beginning on page S-6 of the ATM Prospectus and in the documents incorporated by reference in the ATM Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

<div align='center'>Piper Sandler

The date of this prospectus supplement is June 23, 2025.</div>